Accurate dosing with enhanced palatability

Liquid formulations for pediatric and geriatric patients pose issues of manufacture, stability, transportation and precision in measurement of the dose. A satisfactory means of achieving a liquid form for use after reconstitution from a solid format is highly desirable. A significant amount of the active ingredient from a conventional tablet for suspension (TFS) tends to either sediment or adheres to the sides of the container leading to sub-optimal dose administration. RubiDT® provides a unique technology which reduces the movement of the particles of the tablet after reconstitution, thereby ensuring uniformity of the drug content that translates into accurate dosing and desired therapeutic outcome. Moreover it yields as in-situ suspension with options of multiple flavours.

Potential Drug Candidates for RubiDT®
Your Molecule ; Our Technology

Drug molecules which exhibit one or more of following properties are potential candidates for RubiDT®-

  • Pediatric &/or geriatric dosing
  • Unstable in presence of water
  • Narrow therapeutic window
  • Requires accurate dosing
  • Bitter and obnoxious taste
  • High dose
  • Opportunity of LCM

RubiDT® refers to a novel TFS with the unique property of “Reduced Sedimentation Rate” resulting accurate dosing and desired therapeutic outcome. The system contains a high viscosity polymer which upon dissolution increases the viscosity of the dispersion medium, thus reducing the lability of the particles and hence the sedimentation rate. Further the viscolizer provides syrupy consistency which improves mouth feel and palatability. The unique feature of the technology is the rapid disintegration of the tablet despite the presence of the high viscosity polymer.

IP status

The basic technology is protected by patent applications filed in various countries. Additional patent applications have also been filed for expanding the scope of RubiDT® technology.


Key attributes

  • Employs GRAS listed and Pharmacopoeial ingredients
  • Suitable for high dose actives
  • Conventional method of manufacture
  • Rapid disintegration at reconstitution
  • Accuracy of Dosing
  • Improved palatability
  • Reduction in variability of response
  • Good stability profile

Taste-masked, dispersible tablets of an anti bacterial agent

A tablet for suspension was developed for an antibacterial agent, for which the current product in the market is a powder for suspension with a limited shelf life of 21 days post reconstitution. The Rubicon developed TFS provided, after reconstitution, reduced rate of sedimentation, improved taste and mouthfeel and an in-vitro release profile similar to marketed formulation

Challenges and achievements

  • Considerably reduced sedimentation rate
  • Uniformity of dosing
  • Superior taste and palatability
  • Similar drug release profile